Real-World Insights: Multiple Myeloma Treatment Challenges

EP: 1.Unmet Needs In Multiple Myeloma Management

EP: 2.Evolving Goals in Multiple Myeloma Treatment

EP: 3.Multiple Myeloma Induction Challenges and Future Options

EP: 4.Optimizing Multiple Myeloma Treatment: Quadruplet Therapy

Now Viewing

EP: 5.Real-World Insights: Multiple Myeloma Treatment Challenges

EP: 6.Navigating the Multiple Myeloma Treatment Landscape

EP: 7.Real-world Multiple Myeloma Treatment: Insights and Challenges

EP: 8.The Future of Multiple Myeloma Treatment

EP: 9.ASH 2023: Multiple Myeloma's Shifting Landscape: Trials and Clinical Perspectives

EP: 10.Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs

This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.

Richter explores the role of real-world data (RWD) in complementing randomized phase 2 and 3 clinical trials. Davies expresses belief in RWD, highlighting its significance in understanding patient populations not included in clinical trials due to strict entry criteria. While acknowledging RWD's value, Davies notes its potential limitations due to variations in data collection standards. Abonour emphasizes the evolving landscape with electronic medical records improving data granularity. Krishnan discusses the relevance of RWD in underserved populations and advanced relapsed disease, citing examples where RWD supplements trial data and provides valuable insights into areas where trials fall short.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.